QCG
IGMS

Quadrant Capital Group’s IGM Biosciences IGMS Stock Holding History

Quadrant Capital Group’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-96
Closed -$1.32K – 2727
2023
Q1 		$1.32K Sell
96
-116
-55% -$2.4K ﹤0.01% 2501
2022
Q4 		$3.61K Buy
212
+116
+121% +$2.32K ﹤0.01% 2283
2022
Q3 		$2K Hold
96
– – ﹤0.01% 2385
2022
Q2 		$2K Sell
96
-77
-45% -$1.37K ﹤0.01% 2225
2022
Q1 		$5K Buy
+173
New +$3.22K ﹤0.01% 1910
2021
Q4 		– Sell
-27
Closed -$2K – 2595
2021
Q3 		$2K Buy
+27
New +$2.07K ﹤0.01% 2151

Other funds holding IGMS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Quadrant Capital Group's IGMS Position: Q2 2023 in Review

Quadrant Capital Group sold out of IGM Biosciences (IGMS) in Q2 2023, closing a stake of 96 shares — an estimated $1.32K sold.

Quadrant Capital Group first reported a position in IGMS in Q3 2021 and held it in 6 quarters. The position peaked at $5K in Q1 2022. 79 funds tracked by Wall St. Rank hold IGMS as of Q2 2023.

  • Quadrant Capital Group reported no remaining IGM Biosciences position as of Q2 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 96 IGM Biosciences shares in Q2 2023, an estimated $1.32K.
  • Quadrant Capital Group first reported a position in IGM Biosciences in Q3 2021 and held it in 6 quarters.
  • Quadrant Capital Group's IGM Biosciences position peaked at $5K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.